



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Apomorphine (Non-PDL)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, etc.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Questions Q1-Q6 regarding renewal, criteria, side effects, improvement, treatment plan, and diagnosis.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Apomorphine (Non-PDL)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q7. Is the medication being prescribed by or in consultation with a specialist (who specializes in the treatment of PD or a neurologist)?
Q8. Does the patient have a history of therapeutic failure, a contraindication to or intolerance of the preferred Antiparkinson's agents...
Q9. Will the initial "test" dose be given under medical supervision?
Q10. Will the medication ONLY be given via subcutaneous route of administration?
Q11. Will trimethobenzamide be started 3 days prior to the initial dose of Apomorphine...
Q12. Will this medicine be administered with 5HT3 antagonists...
Q13. Has renal function been evaluated and has medication been dose adjusted for renal impairment...
Q14. Has a cardiac evaluation been performed...
Q15. Has the patient been counseled on the risks of using alcohol, antihypertensive medications, and vasodilating medications...
Q16. Will the patient abstain from alcohol while taking this medicine?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Apomorphine (Non-PDL)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q17. Is the treatment plan attached showing how the medication will be administered, duration of therapy, and other medications that will be continued?

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q18. Is each dose less than or equal to 0.6 mL with a dosing frequency of less than or equal to five times per day?

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q19. Additional Information:

Prescriber Signature

Date

Updated for 2023